Asset Details
Do you wish to reserve the book?
Global burden of MAFLD, MAFLD related cirrhosis and MASH related liver cancer from 1990 to 2021
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Global burden of MAFLD, MAFLD related cirrhosis and MASH related liver cancer from 1990 to 2021
Do you wish to request the book?
Global burden of MAFLD, MAFLD related cirrhosis and MASH related liver cancer from 1990 to 2021
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Global burden of MAFLD, MAFLD related cirrhosis and MASH related liver cancer from 1990 to 2021
2025
Overview
Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most prevalent chronic liver disease globally, driven by rising obesity, metabolic syndrome (MetS), and type 2 diabetes mellitus (T2DM). This study evaluates the global, regional, and national burden of MAFLD-related diseases from 1990 to 2021 and projects future trends. Data were sourced from the Global Burden of Disease (GBD) 2021 database, including estimates for the incidence, prevalence, mortality, and disability-adjusted life years (DALYs) associated with MAFLD, MAFLD-related cirrhosis, and MASH-related liver cancer. Countries were classified into 21 regions and five socio-demographic index (SDI) quintiles to analyze health disparities. Decomposition analyses assessed the contributions of population growth, aging, and epidemiological shifts. Future trends were modeled using the Bayesian Age-Period-Cohort (BAPC) framework. In 2021, approximately 1.27 billion MAFLD cases were reported globally, with an age-standardized prevalence rate (ASPR) of 15,018 per 100,000. The highest incidence occurred in South and East Asia. Mortality reached 138,328 cases for MAFLD and 97,403 for MAFLD-related cirrhosis. Decomposition analyses highlighted population growth and aging as key drivers. BAPC projections indicate a continued rise in MAFLD burden, particularly in low- and middle-income countries. This study underscores the increasing global burden of MAFLD and its complications. Targeted public health interventions focusing on prevention and early management are urgently needed to mitigate future impacts.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Adult
/ Aged
/ Aging
/ Cancer
/ Cross-country inequality analysis
/ Diabetes mellitus (non-insulin dependent)
/ Disability-Adjusted Life Years
/ Female
/ Global Burden of Disease - trends
/ Humanities and Social Sciences
/ Humans
/ Joinpoint regression analysis
/ Liver Cirrhosis - epidemiology
/ Liver Neoplasms - epidemiology
/ Male
/ Metabolic dysfunction-associated fatty liver disease
/ Non-alcoholic Fatty Liver Disease - complications
/ Non-alcoholic Fatty Liver Disease - epidemiology
/ Science
/ Trends
